BLPN submitted an official letter to the SEC on March 4th, opening a petition for rulemaking, the first official step required before any regulatory change can happen.
Public source
Publisher name
Public post
Six months ago, Brian P. Christie and the BLPN community set out to change policy around life science funding. Back in February, right after JPM Week, Brian laid out the…
Company
BLPN
An invite-only,Member-led Club gathering Life Science Dealmakers with a shared goal of helping each other.
- Industry
- Industry Associations
- Location
- The Bullpen, US
- Company size
- 51–200 employees
About BLPN
An invite-only, Member-led Club gathering Life Science Dealmakers with a shared goal of helping each other. Together, we prepare for and attend premier industry events. BLPN Members represent diverse sectors including public and private companies, funds, offices, strategics, bankers, brokers, agencies, accelerators, studios, associations, non-profits, institutions and other critical entities.
See moreLatest activity
Latest activity from BLPN
7 signals
Presence & Recognition
BLPN hosted a Brain Health Master Panel on Wednesday, Sept 9th, featuring 150+ founders, investors, operators, clinicians, investment bankers, strategic acquirers, and Life Sciences leaders to explore brain health.
Presence & Recognition
BLPN members received 12 life science developments worth understanding in comments this week.
People
BLPN is offering a complimentary pitch deck review to other members, particularly relevant for BioTools leaders.
Discover more
Similar signals
Similar public activity from other companies.
Legal & Regulatory
BCLP
BCLP reports that the SEC has proposed rescinding Rule 206(4)-5, commonly known as the pay-to-play rule, which would remove political contribution restrictions and recordkeeping requirements while leaving existing obligations in place.
Legal & Regulatory
Life Science Leader
Life Science Leader reports that a recent Nasdaq rule change introduces a new continued-listing standard tied to market value of listed securities (MVLS) for micro-cap and development-stage life sciences companies.
Legal & Regulatory
Biotechnology Innovation Organization
Biotechnology Innovation Organization's lead negotiator broke down what's in the FDA's PDUFA VIII commitment letter regarding new efficiencies and leveraging existing biotech system strengths.
Legal & Regulatory
Investment Company Institute
Investment Company Institute is working with the U.S. Securities and Exchange Commission on the rescission of the Political Contribution Rule for Investment Advisers to ensure equal opportunity for financial services professionals to participate in democratic processes.
Legal & Regulatory
AdAstra BIO